Op2Lysis is a pre-clinical stage biotech company developing O2L-001, a unique solution for hemorrhagic stroke patients.
O2L-001 (derived from the NANOp2Lysis proprietary platform) is the first effective and safe treatment to remove intracerebral hematoma and reduce disability and death following acute hemorrhagic stroke. It has been tailored to be locally injected, through micro-invasive surgery, via a catheter at the core of the hematoma. The main characteristics of O2L-001 are:
- EASY to use, simplified model of administration (unique injection)
- EFFECTIVE with better thrombolytic effect on best translational model (vs gold standard)
- SAFE, reduced side effect (bleeding and neurotoxoxicity vs gold standard)
Op2Lysis core team is composed of 6 people with complementary competencies and skills. This project team is staffed to lead O2L-001 toward the clinic as several activities are subcontracted due to the strict regulation of drug development.
The team (alphabetic order)
Acute hemorrhagic stroke is an unmet medical need that affects >350 000p yearly in the European Union, USA and in Japan. Healthcare is restricted to intensive nursing and monitoring. As a consequence of the severity of the disease and of the absence of treatment, 75% of AHS patients die and have severe disability. Up to now, stopping the bleeding early or neuroprotection of the brain did not show any positive effect in clinical trials. Hematoma evacuation by a surgical approach was not beneficial neither. Nevertheless, one recent clinical trial opened a new hope. While the MisTIE program failed to demonstrate a clinical benefit with the gold standard thrombolytic agent to evacuate the hematoma, this trial also highlighted for the first time a strong relationship between the volume of hematoma evacuated and the level of handicap one year after treatment. Thus, data from the real-world needs (patients) help us in designing our therapeutic solution (O2L-001), to promote higher efficacy and safety.
Op2Lysis offices are located in Caen (FR) and in Liège (BE) where the company benefits from the very active networks:
Close connection with an Inserm-Université de Caen research unit, where the drug substance was invented. The company has an access to state-of-the-art laboratories (Cyceron Center).
Close connection with the emerging biotech ecosystem in Liège area (Accessia Pharma)